These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9155518)

  • 1. Tumour biological features of BRCA1-induced breast and ovarian cancer.
    Jóhannsson OT; Idvall I; Anderson C; Borg A; Barkardóttir RB; Egilsson V; Olsson H
    Eur J Cancer; 1997 Mar; 33(3):362-71. PubMed ID: 9155518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.
    van der Groep P; Bouter A; van der Zanden R; Siccama I; Menko FH; Gille JJ; van Kalken C; van der Wall E; Verheijen RH; van Diest PJ
    J Clin Pathol; 2006 Jun; 59(6):611-7. PubMed ID: 16603649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
    Borg A; Dørum A; Heimdal K; Maehle L; Hovig E; Møller P
    Dis Markers; 1999 Oct; 15(1-3):79-84. PubMed ID: 10595257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.
    Eerola H; Heikkilä P; Tamminen A; Aittomäki K; Blomqvist C; Nevanlinna H
    Breast Cancer Res; 2005; 7(1):R93-100. PubMed ID: 15642173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
    Verhoog LC; van den Ouweland AM; Berns E; van Veghel-Plandsoen MM; van Staveren IL; Wagner A; Bartels CC; Tilanus-Linthorst MM; Devilee P; Seynaeve C; Halley DJ; Niermeijer MF; Klijn JG; Meijers-Heijboer H
    Eur J Cancer; 2001 Nov; 37(16):2082-90. PubMed ID: 11597388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.
    Eerola H; Heikkilä P; Tamminen A; Aittomäki K; Blomqvist C; Nevanlinna H
    Breast Cancer Res; 2005; 7(4):R465-9. PubMed ID: 15987451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
    Zweemer RP; Shaw PA; Verheijen RM; Ryan A; Berchuck A; Ponder BA; Risch H; McLaughlin JR; Narod SA; Menko FH; Kenemans P; Jacobs IJ
    J Clin Pathol; 1999 May; 52(5):372-5. PubMed ID: 10560359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics of selected features of hereditary ovarian cancer in carriers of constitutional BRCA1 gene mutation].
    Menkiszak J; Górski B; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Foszczyńska-Kłoda M; Fliciński J; Brzosko M; Rzepka-Górska I; Jan L
    Ginekol Pol; 2002 Nov; 73(11):1084-9. PubMed ID: 12722403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study.
    Pérez-Vallés A; Martorell-Cebollada M; Nogueira-Vázquez E; García-García JA; Fuster-Diana E
    J Clin Pathol; 2001 Jun; 54(6):476-80. PubMed ID: 11376024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyses of p53 expression pattern and BRCA mutations in patients with double primary breast and ovarian cancer.
    Bruchim I; Fishman A; Friedman E; Goldberg I; Chetrit A; Barshack I; Dekel E; Hirsh-Yechezkel G; Modan B; Kopolovic J
    Int J Gynecol Cancer; 2004; 14(2):251-8. PubMed ID: 15086724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.
    Chang-Claude J; Dong J; Schmidt S; Shayeghi M; Komitowski D; Becher H; Stratton MR; Royer-Pokora B
    J Med Genet; 1998 Feb; 35(2):116-21. PubMed ID: 9507390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
    de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
    Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
    Einbeigi Z; Bergman A; Meis-Kindblom JM; Flodin A; Bjursell C; Martinsson T; Kindblom LG; Wahlström J; Wallgren A; Nordling M; Karlsson P
    Fam Cancer; 2007; 6(1):35-41. PubMed ID: 16944270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma.
    Borg A; Isola J; Chen J; Rubio C; Johansson U; Werelius B; Lindblom A
    Int J Cancer; 2000 Mar; 85(6):796-800. PubMed ID: 10709098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
    Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
    Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.